Articles from Lycia Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the completion of an oversubscribed $75 million Series D financing. The company also announced the appointment of Amy Bachrodt as Chief Financial Officer and the promotion of Karen Flick to General Counsel.

Dr. Lee will oversee the clinical development of Lycia’s lead programs, LCA-0061 for IgE-mediated diseases and LCA-0321 for Graves’ disease

SOUTH SAN FRANCISCO, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced that Aetna Wun Trombley, Ph.D., President and Chief Executive Officer of Lycia, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:00 pm ET in New York.

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced that founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry. The Royal Swedish Academy of Sciences recognized Dr. Bertozzi for her pioneering work in bioorthogonal chemistry that enabled researchers to interrogate molecules in living systems with click chemistry. The Prize was also awarded to Morten Meldal, professor at University of Copenhagen, and K. Barry Sharpless, professor at Scripps Research, for laying the foundation for a functional form of click chemistry in which molecular building blocks snap together quickly and efficiently.